Table 2.
Clinical Characteristics of T1DM and T2DM Study Participants at Dessie Referral Hospital, Northeast Ethiopia from February to April 2019 (N=120)
| Variables | Category | T1DM; N=60 n (%) | T2DM; N=60 n (%) |
|---|---|---|---|
| Medication Regimen | Insulin | 60(100) | – |
| Metformin | - | 37 (61.6) | |
| Glibenclamide | - | 7 (11.7) | |
| Metformin and Glibenclamide | - | 12 (20.0) | |
| Insulin and Oral hypoglycaemic Agents | - | 4 (6.7) | |
| Diabetic Ketoacidosis | Yes | 4 (6.7) | - |
| No | 56 (93.3) | 60 (100) | |
| HHS | Yes | 1 (1.7) | 1 (1.7) |
| No | 59 (98.3) | 59 (98.3) | |
| Foot ulcer | Yes | - | 3 (5.0) |
| No | 60 (100) | 57 (95.0) | |
| Visual Disturbance | Yes | - | 4 (6.7) |
| No | 60 (100) | 56 (93.3) | |
| Neuropathy | Yes | 1 (1.7) | 2 (3.3) |
| No | 59 (98.3) | 58 (96.7) | |
| Duration of Treatment | 0–5 years | 38 (63.3) | 33 (55.0) |
| 6–10 years | 17 (28.3) | 7 (28.3) | |
| > 10 years | 5 (8.3) | 10 (16.7) | |
| Duration of DM | 0–5 years | 38 (63.3) | 33 (55.0) |
| 6–10 years | 17 (28.3) | 7 (28.3) | |
| > 10 years | 5 (8.3) | 10 (16.7) |
Abbreviations: IQR, interquartile range; HHS, hyperglycemic hyperosmolar state; FBG, fasting blood glucose.